2. Search Result
Search Result
Results for "

Palmitoyl CoA

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Biochemical Assay Reagents

13

Peptides

1

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136408
    Malonyl CoA lithium

    Malonyl coenzyme A lithium

    		 Carnitine Palmitoyltransferase (CPT) Mitochondrial Metabolism Metabolic Disease
    Malonyl CoA (Malonyl Coenzyme A) lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl CoA lithium concentrations suppress fatty acid oxidation, while low Malonyl CoA lithium concentrations are permissive for fat oxidation .
    Malonyl CoA lithium
  • HY-134427
    Palmitoyl coenzyme A lithium
    2 Publications Verification

    Palmitoyl CoA lithium

    		 Endogenous Metabolite Metabolic Disease
    Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis .
    Palmitoyl coenzyme A lithium
  • HY-P0064
    Palmitoyl Tetrapeptide-3

    Palmitoyl Tetrapeptide-7

    		 Interleukin Related Inflammation/Immunology
    Palmitoyl Tetrapeptide-3 (Palmitoyl Tetrapeptide-7) is a synthetic peptide corresponding to amino acids 341-344 of the human immunoglobulin heavy chain, with the ability to stimulate phagocytosis. Palmitoyl tetrapeptide-3 reduces interleukin-6 (IL-6) secretion in keratinocytes and inhibits the UVB radiation-exposure inflammatory response of skin. Palmitoyl tetrapeptide-3 It also has anti-inflammatory and anti-aging effects, reducing skin wrinkles by promoting the production of elastic fibers in the papillary dermis .
    Palmitoyl Tetrapeptide-3
  • HY-P10932A
    pGk13a TFA

    		Fluorescent Dye Neurological Disease
    pGk13a TFA is an azide (azide group can be combined with fluorophore)-containing amphiphilic membrane labeling probe. pGk13a TFA enables high-resolution imaging of cell membranes in the ultrastructural membrane expansion microscopy (umExM) technique, facilitating the observation of membrane-associated structures and proteins. pGk13a TFA can be used for neuronal structural studies .
    pGk13a TFA
  • HY-B1880
    Oxadiazon

    		Environmental Pollutants Cytochrome P450 Herbicide Neurological Disease Metabolic Disease
    Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .
    Oxadiazon
  • HY-139451
    ELOVL6-IN-3

    		ELOVL Neurological Disease
    ELOVL6-IN-1 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-1 dose-dependently inhibits mouse ELOVL6 activities, with an IC50 value of 0.350 μM. ELOVL6-IN-1 inhibits ELOVL6 in a noncompetitive manner for malonyl-CoA (Ki=994 nM) and palmitoyl-CoA .
    ELOVL6-IN-3
  • HY-P10031
    SAR441255

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
    SAR441255
  • HY-W688565
    (2S)-2-Amino-1-hydroxyoctadecan-3-one

    		Ceramidase Metabolic Disease
    (2S)-2-Amino-1-hydroxyoctadecan-3-one is the product generated by the decarboxylative condensation of L-serine and palmitoyl-CoA catalyzed by serine palmitoyltransferase (SPT) .
    (2S)-2-Amino-1-hydroxyoctadecan-3-one
  • HY-P10932
    pGk13a

    		Fluorescent Dye Neurological Disease
    pGk13a is an amphipathic membrane-labeling probe containing an azide group, which can bind to fluorophores. pGk13a enables high-resolution imaging of cell membranes in the ultrastructure expansion microscopy (umExM) technique, facilitating the observation of membrane-associated structures and proteins. pGk13a is applicable to neuronal structure research .
    pGk13a
  • HY-B1880R
    Oxadiazon (Standard)

    		Herbicide Reference Standards Cytochrome P450 Neurological Disease Metabolic Disease
    Oxadiazon (Standard) is the analytical standard of Oxadiazon (HY-B1880). This product is intended for research and analytical applications. Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .
    Oxadiazon (Standard)
  • HY-P10380
    palm11-PrRP31

    		Neuropeptide FF Receptor Neurological Disease Metabolic Disease
    palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
    palm11-PrRP31
  • HY-E70264
    16:0 Coenzyme A triammonium

    		Endogenous Metabolite Metabolic Disease
    16:0 Coenzyme A triammonium is palmitoyl-CoA, which can serve as a reaction substrate to transfer the palmitoyl group to the free thiol group of the target protein through palmitoylation catalyzed by protein acyl transferases (PATs) .
    16:0 Coenzyme A triammonium
  • HY-179170S
    Malonyl CoA-13C3 lithium

    Malonyl coenzyme A-13C3 lithium

    		 Isotope-Labeled Compounds Mitochondrial Metabolism Carnitine Palmitoyltransferase (CPT) Metabolic Disease
    Malonyl CoA- 13C3 (Malonyl coenzyme A- 13C3) lithium is the 13C-labeled Malonyl CoA lithium (HY-136408). Malonyl CoA (Malonyl Coenzyme A) lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl CoA lithium concentrations suppress fatty acid oxidation, while low Malonyl CoA lithium concentrations are permissive for fat oxidation .
    Malonyl CoA-13C3 lithium
  • HY-P10031A
    SAR441255 TFA

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .
    SAR441255 TFA
  • HY-166328
    Palmitoyl coenzyme A potassium

    Palmitoyl CoA potassium

    		 Biochemical Assay Reagents Metabolic Disease
    Palmitoyl coenzyme A (potassium) (Palmitoyl CoA (potassium)) is an ester product.
    Palmitoyl coenzyme A potassium
  • HY-P10380A
    palm11-PrRP31 TFA

    		Neuropeptide FF Receptor Neurological Disease Metabolic Disease
    palm11-PrRP31 TFA is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 TFA is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 TFA is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 TFA can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
    palm11-PrRP31 TFA
  • HY-E70252
    1-Pyrenebutanoyl-CoA

    S-1-Pyrenebutanoate-CoA; Coenzyme A,S-1-pyrenebutanoate

    		 Endogenous Metabolite Cardiovascular Disease
    1-Pyrenebutanoyl-CoA is a type of coenzyme A that can non-competitively inhibit (Ki = 2 μM) phosphorylating (ADP-stimulated) respiration in rat liver mitochondria, and competitively inhibit (Ki = 2.1 μM and 15 μM) carnitine palmitoyl-CoA transferase and octanoyl-CoA transferase .
    1-Pyrenebutanoyl-CoA
  • HY-P10379
    palm-PrRP31

    		Neuropeptide FF Receptor Others Neurological Disease
    palm-PrRP31 is a potent dual receptor agonist for both GPR10 (EC50=72 pM) and NPFF-R2. palm-PrRP31 activates downstream signaling pathways through binding to its receptors, GPR10 and NPFF-R2, which results in reduced appetite and increased energy expenditure. Utilizing palm-PrRP31 facilitates the study of the mechanism of action in the nervous system, thereby elucidating the complex biological processes that regulate appetite and energy expenditure .
    palm-PrRP31
  • HY-P5954
    PLTX-II

    		Calcium Channel Others
    PLTX-II is a calcium channel blocker. PLTX-II has a 44-residue peptide containing ten Cys residues and an O-palmitoylated threonine amide at the carboxy-terminus .
    PLTX-II
  • HY-P2739A
    Citrate Synthase, Porcine

    		Endogenous Metabolite Metabolic Disease
    Citrate Synthase, Porcine (EC 4.1.3.7), catalyzes the conversion of citrate to acetyl-CoA in the presence of coenzyme A, releasing water and oxaloacetate. Citrate Synthase can be inhibited by fluoroacetyl-CoA, palmitoyl-CoA, and citrate-CoA.
    Citrate Synthase, Porcine
  • HY-P2739B
    Citrate Synthase, Pigeon

    		Biochemical Assay Reagents Metabolic Disease
    Citrate Synthase, Pigeon (EC 4.1.3.7) catalyses the conversion of Citrate to acetyl-CoA in the presence of coenzyme-A with the release of H2O and oxaloacetate. Citrate Synthase, Pigeon (EC 4.1.3.7) is inhibited by fluoroacetyl-CoA, palmitoyl-CoA, and citroyl-CoA.
    Citrate Synthase, Pigeon
  • HY-182539
    DD04107

    		CGRP Receptor Others Neurological Disease
    DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Ka of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .
    DD04107
  • HY-182438
    SDZ 51641

    		Drug Intermediate Metabolic Disease
    SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research .
    SDZ 51641

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: